Prevalence of Cardiovascular Risk Factors in Upper Vestibular Neuritis (NEVRITE)

October 6, 2021 updated by: University Hospital, Strasbourg, France

Prevalence of Cardiovascular Risk Factors in People With Upper Vestibular Neuritis

Vestibular neuritis is the second cause of vertigo, it constitutes 5 to 6% of the aetiologies of vertigo in an otoneurological consultation.

Infection or reactivation of a neurotropic virus of the herpes group (HSV-1) in the vestibular lymph node is thought to be the cause of the unilateral vestibular deficit.

Upper vestibular neuritis is more common than lower, or total involvement. Goebel (2) explains this by an anatomical predisposition of the vestibular nerve canal to inflammation, unlike the singular nerve canal which is shorter and wider giving way to a certain degree of edema without consequence on its contents.

However, the innervation territory of the superior vestibular nerve is superimposable on the territory supplied by the anterior vestibular artery. The anterior, lateral semicircular canals and the utricle are affected. Current complementary vestibular and imaging examinations cannot differentiate between inflammatory or vascular involvement in upper vestibular neuritis.

The increased presence of cardiovascular risk factors in patients with upper vestibular neuritis would be an argument in favor of ischemic involvement of the anterior vestibular artery.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service ORL et de CCF - Hôpitaux Universitaires de Strasbourg
        • Contact:
        • Sub-Investigator:
          • Pauline Pâris, MD
        • Sub-Investigator:
          • Idir DJENNAOUI, MD
        • Sub-Investigator:
          • Pierre MAHOUDEAU, MD
        • Sub-Investigator:
          • Pierre ETOURNEAU, MD
        • Sub-Investigator:
          • Julien GODET, Engineer

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Major having presented an episode of upper vestibular neuritis recorded on the Video Head Impulse Test Ulmer device at the HUS between 01/01/2016 and 01/31/2020,

Description

nclusion criteria:

  • Major subject (≥18 years old),
  • Subject having presented an episode of upper vestibular neuritis recorded on the Video Head Impulse Test Ulmer device at the HUS between 01/01/2016 and 01/31/2020,
  • Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion criteria:

  • Patient who expressed his opposition to participating in the study,
  • Total vestibular neuritis,
  • impossibility of providing the subject with enlightened information (difficulties in understanding the subject, etc.)
  • Subject under safeguard of justice,
  • Subject under guardianship or guardianship,
  • Lack of video head impulse test data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Retrospective study of cardiovascular risk factors in people with upper vestibular neuritis
Time Frame: Files analysed retrospectively from January 01, 2016 to January 31, 2020 will be examined]
Files analysed retrospectively from January 01, 2016 to January 31, 2020 will be examined]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Investigators

  • Study Director: Anne CHARPIOT, MD, PhD, Service ORL et de CCF- Hôpitaux Universitaires de Strasbourg

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2020

Primary Completion (Anticipated)

February 1, 2022

Study Completion (Anticipated)

February 4, 2022

Study Registration Dates

First Submitted

June 4, 2021

First Submitted That Met QC Criteria

June 8, 2021

First Posted (Actual)

June 15, 2021

Study Record Updates

Last Update Posted (Actual)

October 7, 2021

Last Update Submitted That Met QC Criteria

October 6, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7665

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe